SCHEMBL544243

SCHEMBL544243

Nc1ccnc2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.54
MAPT P10636 6/20 0.46
HSP90AA1 P07900 5/20 0.46
HSP90AB1 P08238 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
APAF1 O14727 1/20 0.46
TDP2 O95551 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
LMNA P02545 4/20 0.45
HTT P42858 3/20 0.45
HIF1A Q16665 2/20 0.45
BLM P54132 1/20 0.45
PRMT5 O14744 1/20 0.44
NR4A2 P43354 2/20 0.42
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26697692 0.98 NCF1 (0.52) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL27697571 0.86 HSP90AA1 (0.44) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
Water SCHEMBL27717949 0.84 HSP90AA1 (0.42) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL825817 0.84 MAPT (0.54) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL16381310 0.77 NR4A2 (0.48) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL30906615 0.76 KDM4E (0.50) NCF1MAPTHSP90AA1ALDH1A1MEN1
8-Aminoquinoline SCHEMBL860459 0.75 LMNA (0.53) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL4554547 0.74 PSMD14 (0.56) NCF1MAPTHSP90AA1ALDH1A1MEN1
SCHEMBL204153 0.74 KDM4E (0.44) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1
SCHEMBL3350823 0.74 NCF1 (0.60) NCF1MAPTHSP90AA1HSP90AB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615537-A2 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS Novartis AG (CH) 2020-03-04 EP claimed
WO-2018198077-A2 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2018-11-01 WO claimed
EP-2699572-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 EP claimed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 WO claimed
CN-101175493-A Method for treating actinic keratosis 3M INNOVATIVE PROPERTIES CO (US) 2008-05-07 CN claimed
CN-101155813-A Ethanesulfonic acid salt of 1- (2-methylpropyl) -1H-imidazo [4, 5-C ] [1,5] naphthyridin-4-amine and methanesulfonic acid salt of 1- (2-methylpropyl) -1H-imidazo [4, 5-C ] [1,5] naphthyridin-4-amine TAKEDA PHARMACEUTICAL (JP) 2008-04-02 CN claimed
CN-101146807-A Process for the preparation of 2-methyl-1- (2-methylpropyl) -1H-imidazo [4, 5-C ] [1,5] naphthyridin-4-amine 3M INNOVATIVE PROPERTIES CO (US) 2008-03-19 CN claimed
CN-1845736-A Methods related to the treatment of mucosal associated conditions 3M INNOVATIVE PROPERTIES CO (US) 2006-10-11 CN claimed
EP-1450804-A1 PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER 3M Innovative Properties Company (US) 2004-09-01 EP claimed
CN-1147493-C Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof 3M 2004-04-28 CN claimed
WO-2003045391-A1 PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-05 WO claimed
EP-1075478-B1 PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2003-04-16 EP claimed
CN-1320126-A Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2001-10-31 CN claimed
WO-2025039979-A1 PROTEIN ARGININE METHYLTRANSFERASE-5 INHIBITOR AND PHARMACEUTICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-02-27 WO disclosed
US-20240343710-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. 2024-10-17 US disclosed
CN-113166143-B N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 舒万诺知识产权公司 2024-06-04 CN disclosed
US-4347362-A HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1982-08-31 US disclosed
US-4324893-A 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1982-04-13 US disclosed
EP-0018735-A1 1,8-Naphthyridine derivatives, their preparation, pharmaceutical compositions containing them AMERICAN HOME PRODUCTS CORPORATION (US) 1980-11-12 EP disclosed
WO-1980002287-A1 1,8-NAPHTHYRIDINE DERIVATIVES AMERICAN HOME PROD (US) 1980-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343710-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PARP1, PARP11, PARP12 NCF1 1065/4885MAPT 4689/4885HSP90AA1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.